Anti Cd30 Therapies Pipeline Insight
DelveInsight’s, “Anti-CD30 Therapies - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD30 Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Anti-CD30 Therapies Understanding
Anti-CD30 Therapies: Overview
CD30 (also known as TNFRSF8) is a 120-kD transmembrane protein of the tumor necrosis factor family. The protein is comprised of an extracellular domain, a transmembrane region and a cytoplasmic domain. The majority of antibodies against human CD30 recognize epitopes within the extracellular domain. CD30 signaling regulates peripheral T-cell responses, controlling T-cell survival, and downregulating cytolytic capacity. CD30 is expressed on activated T cells, NK cells, and B cells. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. Studies have also shown a role of CD30 as a T-cell costimulatory molecule involved in Th1, Th2, and Th17 immune responses. The restriction of CD30 expression on normal cells makes it an attractive candidate for targeted therapy. In studies, anti-CD30 antibodies alone display therapeutic efficacy, the newer agents markedly enhance antibody effectiveness through their conjugation with various cytotoxic agents. Hence, CD30 can serve both as a diagnostic marker for lymphocyte malignancies and as a target for therapy.
The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD30 Therapies R&D. The therapies under development are focused on novel approaches for Anti-CD30 Therapies.
Anti-CD30 Therapies Emerging Drugs Chapters
This segment of the Anti-CD30 Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD30 Therapies Emerging Drugs
Brentuximab vedotin - Seagen/Takeda
Brentuximab Vedotin (ADCETRIS) is an antibody-drug conjugate (ADC) therapy developed by Seagen and its Takeda Oncology. The ABC contains an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary technology. This linker system makes the molecule stable in the bloodstream but to release MMAE upon internalization into CD30-expressing cells. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights to commercialize ADCETRIS in the rest of the world.
AFM13 is a tetravalent bispecific chimeric (anti-human CD30 x anti-human CD16A) recombinant antibody construct which is being developed to treat CD30-positive malignancies. The molecule is currently in Phase II clinical evaluation for the treatment of Relapsed/Refractory CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides.
Further product details are provided in the report……..
Anti-CD30 Therapies: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD30 Therapies drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Anti-CD30 Therapies
There are approx. 10+ key companies which are developing the Anti-CD30 Therapies. The companies which have their Anti-CD30 Therapies drug candidates in the most advanced stage, i.e. Phase III include, Seagen/Takeda.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Anti-CD30 Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Anti-CD30 Therapies: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anti-CD30 Therapies therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD30 Therapies drugs.
Anti-CD30 Therapies Report Insights
- Anti-CD30 Therapies Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Anti-CD30 Therapies Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Anti-CD30 Therapies drugs?
- How many Anti-CD30 Therapies drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD30 Therapies?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD30 Therapies therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anti-CD30 Therapies and their status?
- What are the key designations that have been granted to the emerging drugs?